Literature DB >> 18538271

[Renal carcinoma associated with MiTF/TFE translocation: report of six cases in young adults].

M-C Hintzy1, P Camparo, V Vasiliu, M Peyromaure, A Vieillefond.   

Abstract

OBJECTIVE: The authors present six cases of renal carcinoma associated with MiTF/TFE translocation in young adults. This tumour is one of the newly identified entities of the WHO 2004 classification. MATERIALS: Six patients with MiTF/TFE translocation were identified in a series of 636 adults operated between 2001 and 2005. The diagnosis was based on cytogenetic analysis and immunohistochemistry (IHC) in three patients and IHC alone in the other three patients.
RESULTS: Four women and two men between the ages of 28 and 42 years presented a tumour with a mean diameter of 6 cm (range: 3-15 cm). The TNM classification of these tumours was pT1N0 (n=2), pT2N0 (n=1), pT3aN+M0 (n=1), and pT3aN+M+ (n=2). The mean follow-up was 32 months. One M+ patient died six months after the operation, another two pT3 patients developed metastatic disease and pT1 or pT2 patients were alive without recurrence. The histological features comprised a typical papillary architecture with large eosinophil and/or clear cells. IHC showed TFE3 (n=5) or TFEB (n=1) expression. Cytogenetic analysis demonstrated a t(X;1)(p11.2;p34) or t(X;17)(p11.2;q25) translocation in two patients expressing TFE3 and a t(6;11)(p21; q13) translocation in the patient expressing TFEB.
CONCLUSION: Renal carcinoma associated with MiTF/TFE translocation can be diagnosed by IHC. However, cytogenetic analysis on fresh or frozen material allows characterization of the translocation and should be performed on all renal tumours in young adults. Prognosis is related to stage. In the future, the diagnosis of more cases of this type of carcinoma will allow more precise definition of the clinicopathological profile and the most appropriate management.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18538271     DOI: 10.1016/j.purol.2008.03.026

Source DB:  PubMed          Journal:  Prog Urol        ISSN: 1166-7087            Impact factor:   0.915


  3 in total

1.  Temsirolimus in the treatment of renal cell carcinoma associated with Xp11.2 translocation/TFE gene fusion proteins: a case report and review of literature.

Authors:  Jigarkumar Parikh; Teresa Coleman; Nidia Messias; James Brown
Journal:  Rare Tumors       Date:  2009-12-28

2.  Xp11.2 translocation renal cell carcinoma occurring during pregnancy with a novel translocation involving chromosome 19: a case report with review of the literature.

Authors:  Henry B Armah; Anil V Parwani; Urvashi Surti; Sheldon I Bastacky
Journal:  Diagn Pathol       Date:  2009-05-18       Impact factor: 2.644

3.  Validation and utilization of a TFE3 break-apart FISH assay for Xp11.2 translocation renal cell carcinoma and alveolar soft part sarcoma.

Authors:  Dinesh Pradhan; Somak Roy; Gabriela Quiroga-Garza; Kathleen Cieply; Alyssa L Mahaffey; Sheldon Bastacky; Rajiv Dhir; Anil V Parwani
Journal:  Diagn Pathol       Date:  2015-09-29       Impact factor: 2.644

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.